BRIEF published on 10/24/2024 at 09:35, 28 days 1 hour ago QUANTRO Therapeutics and IMP Form Research Alliance for Drug Discovery Drug Discovery Cancer Therapy QUANTRO Therapeutics IMP Collaboration Transcription Factor
PRESS RELEASE published on 10/24/2024 at 09:30, 28 days 1 hour ago QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery QUANTRO Therapeutics partners with IMP to advance transcriptomic drug discovery. Strategic collaboration to explore transcription factors' functions for cancer therapies QUANTRO Therapeutics Transcription Factors IMP Transcriptomic Drug Discovery Cancer Therapies
BRIEF published on 08/06/2024 at 10:05, 3 months 15 days ago QUANTRO Therapeutics Secures Key Austrian Research Grant to Advance Platform Development Drug Discovery QUANTRO Therapeutics FFG Grant Transcriptomic Platform Multiplexing
PRESS RELEASE published on 08/06/2024 at 10:00, 3 months 15 days ago QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform QUANTRO Therapeutics secures Austrian research grant to accelerate cutting-edge platform development, enabling multiplex target screening in drug discovery Drug Discovery QUANTRO Therapeutics Austrian Research Grant Transcriptomic Discovery Platform Multiplexing Capabilities
BRIEF published on 06/04/2024 at 23:12, 5 months 16 days ago QUANTRO Therapeutics Reaches Milestone in Collaboration with Boehringer Ingelheim Cancer Treatments R&D Collaboration Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors
PRESS RELEASE published on 06/04/2024 at 23:07, 5 months 16 days ago QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments QUANTRO Therapeutics achieves key milestone in collaboration with Boehringer Ingelheim for first-in-class cancer treatments using proprietary technology Cancer Treatments Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors R&D Program
PRESS RELEASE published on 04/04/2023 at 09:30, 1 year 7 months ago QUANTRO Therapeutics appoints Industry Expert Dr. Michael Bauer as Chief Executive Officer
Published on 11/21/2024 at 10:03, 32 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 35 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 35 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 10 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 30 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 33 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 35 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 35 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 34 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 37 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 15 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 50 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 50 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
